Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Hepatology"
DOI: 10.1016/s0168-8278(17)31949-9
Abstract: Recent guidelines recommend that patients who failed DAAs treatment with nonstructural protein 5A inhibitors (NS5A) should be retreated 24 weeks with Sofosbuvir (SOF) combined with either a protease inhibitor for those with NS5A RAVs, or… read more here.
Keywords: active antivirals; antivirals genotype; genotype chronic; retreatment ... See more keywords
Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
Sign Up to like & getrecommendations! Published in 2017 at "Hepatology Research"
DOI: 10.1111/hepr.12910
Abstract: From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one of the standards of care for genotype 1b chronic hepatitis C in Japan, could be possible in patients with impaired renal function. The aim of this… read more here.
Keywords: genotype chronic; efficacy safety; ombitasvir paritaprevir; paritaprevir ritonavir ... See more keywords
Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.14447
Abstract: This study aimed to evaluate the efficacy and safety of elbasvir/grazoprevir in genotype 1b chronic hepatitis C Japanese patients with chronic kidney disease (CKD), including those undergoing hemodialysis. read more here.
Keywords: elbasvir grazoprevir; safety elbasvir; genotype chronic; efficacy safety ... See more keywords